|
Post by traderdennis on Jan 16, 2018 20:52:10 GMT -5
I don't think it's in the financial interest of shorts to post FUD, but many of them do think that -- especially those who post on StockTwits and Yahoo. In my opinion only, I believe there are "longs" on this board who are really short posting unrealistic expectations of the company to create long demand.
|
|
|
Post by cjm18 on Jan 16, 2018 21:16:49 GMT -5
I don't think it's in the financial interest of shorts to post FUD, but many of them do think that -- especially those who post on StockTwits and Yahoo. In my opinion only, I believe there are "longs" on this board who are really short posting unrealistic expectations of the company to create long demand. Why would shorts want to create long demand.
|
|
|
Post by dreamboatcruise on Jan 16, 2018 21:20:31 GMT -5
That’s exactly right! I use ST for all my other stocks to get quick information, to see when earnings were announced. Upgrades or downgrades. Then I look at my chart app. And I maybe make a quick decision to buy or sell. Who in their right mind clicking on MNKD ST would touch the stock with a 10 foot pole! It’s a jungle. It is my belief that the short position in this stock has employed a very effective psychological warfare campaign against this stock. It is multi-level. It uses bash articles in a variety of forums. There are consistent postings that belittle people that own the stock long. They attack people who are successfully using Afrezza. They attack on Twitter, in Stock Twits, on Facebook and even in the comment sections in Web MD. It is brilliant really. The shorts control the price of the stock even on good news days. They mock long term shareholders so that eventually it seems there is just a dark cloud over everything related to MannKind. Because of how effective the negative campaign has been, it has been very difficult to raise funding in the market. Aaaand because it has been difficult to raise funding, they use that to continue beating down any positive news. With enough capital, I can see how a focused short group could kill a company. Concrete good news is something no amount of attacking on twitter would combat. Heck, look at how amazingly successful MNKD was in running the share price up before the PIPE. But there would need to be follow through in delivering things that were presented/hinted in architecting that run up to recapture those gains. It's lack of institutional investors that is holding price down. If we had institutional interest the shorts wouldn't have a playground. And it's not the short noise that is keeping institutional investors away... they aren't reading twits and facebook, etc.
|
|
|
Post by akemp3000 on Jan 16, 2018 21:28:53 GMT -5
Stay calm CCI. This is not a temporary battle but a war that we will absolutely win. The science will prevail. All the shorting and day trading is just noise while the industry transitions to CGMs, time-in-range and Afrezza. Congrats to those who've made some money playing the evil empire game but the really BIG win is coming soon to the longs...IMHO
|
|
|
Post by brotherm1 on Jan 16, 2018 21:42:24 GMT -5
It is my belief that the short position in this stock has employed a very effective psychological warfare campaign against this stock. It is multi-level. It uses bash articles in a variety of forums. There are consistent postings that belittle people that own the stock long. They attack people who are successfully using Afrezza. They attack on Twitter, in Stock Twits, on Facebook and even in the comment sections in Web MD. It is brilliant really. The shorts control the price of the stock even on good news days. They mock long term shareholders so that eventually it seems there is just a dark cloud over everything related to MannKind. Because of how effective the negative campaign has been, it has been very difficult to raise funding in the market. Aaaand because it has been difficult to raise funding, they use that to continue beating down any positive news. With enough capital, I can see how a focused short group could kill a company. Concrete good news is something no amount of attacking on twitter would combat. Heck, look at how amazingly successful MNKD was in running the share price up before the PIPE. But there would need to be follow through in delivering things that were presented/hinted in architecting that run up to recapture those gains. It's lack of institutional investors that is holding price down. If we had institutional interest the shorts wouldn't have a playground. And it's not the short noise that is keeping institutional investors away... they aren't reading twits and facebook, etc. “It's lack of institutional investors that is holding price down. If we had institutional interest the shorts wouldn't have a playground.” Stocks with la large percentage of institutional investment are not heavily shorted?
|
|
|
Post by traderdennis on Jan 16, 2018 23:19:55 GMT -5
In my opinion only, I believe there are "longs" on this board who are really short posting unrealistic expectations of the company to create long demand. Why would shorts want to create long demand. Hypothetically speaking, say you need to open up a short position of around pen million shares. You pump MNKD to get demand so you can , create a short position. Then say cover your whole bunch of shares with a direct offering.
|
|
|
Post by dreamboatcruise on Jan 16, 2018 23:36:26 GMT -5
Concrete good news is something no amount of attacking on twitter would combat. Heck, look at how amazingly successful MNKD was in running the share price up before the PIPE. But there would need to be follow through in delivering things that were presented/hinted in architecting that run up to recapture those gains. It's lack of institutional investors that is holding price down. If we had institutional interest the shorts wouldn't have a playground. And it's not the short noise that is keeping institutional investors away... they aren't reading twits and facebook, etc. “It's lack of institutional investors that is holding price down. If we had institutional interest the shorts wouldn't have a playground.” Stocks with la large percentage of institutional investment are not heavily shorted? Sometimes you get big money shorts that do their homework and are willing to attack even stocks that Wall Street likes... and sometimes they are correct and see cracks that even institutional shareholders are unaware of. But if a company has the right product, plan and backing of institutional investors the shorts usually can't do much harm. But the bottom line... of my opinion... is that we can't expect to see sustained increase in share price until MNKD manages to start bringing in "real" investors, rather than "retail" investors... maybe some analyst coverage from someone not trying to get fee business.
|
|
|
Post by sportsrancho on Jan 17, 2018 6:45:42 GMT -5
When the real analysts start coming back to the conference calls and asking questions we will have a chance of a real upgrade. This would be the most bullish thing to happen in my mind.
|
|
|
Post by mnholdem on Jan 17, 2018 7:22:21 GMT -5
Mike Castagna had more questions posed by investment analysts at his last presentation than MannKind has had in a couple years of conferences. Can the trend continue?
|
|
|
Post by akemp3000 on Jan 17, 2018 8:07:39 GMT -5
IMO...A nice jump in scripts will come this Q and will be followed by a nice move up in share price...and more institutional investor interest.
|
|
|
Post by peppy on Jan 17, 2018 16:56:48 GMT -5
I wanted to jump in with some real world feedback on the issue of script writing. Don't mean to be a downer, just giving info that board members might find helpful. We at Vdex interface with a lot of providers and a basic principle we operate under is the more experienced a provider is in the field of diabetes, the LESS likely he/she is to recommend Afrezza. It's obviously not 100%, but the phenomenon is common enough to make the point. In other words, those most "in the know" have soured on the product. I won't get into why that is; most here probably already know. The most common feedback we get from such providers is: "Afrezza's a niche product." "It's too expensive." "Patients aren't that interested." Translation for all of these: the provider doesn't really understand the product. I don't think reps calling on busy docs or TV advertising will turn the ship around quickly, if at all. The product is so different. The conditions of the industry are so unfavorable. The incentives work against providers. This product requires a different sales model. Of course, that's self-serving to say. But, that has been our experience. I hope I'm wrong and scripts take off in the new year. But regardless, we'll be fighting the fight either way. I have been thinking about your words. I saw a video interview with a physician saying, "the patients do not mind the needles, the needles are so thin now." I agree that, the needles on the pens are thin. What I think Afrezza needs to hit them with is, "Afrezza keeps their patients glucose from going high in the first place." Perhaps that will be able to be verbalized after the stat trial. I say it now, because I have eyeballs. I understand physicians are only allowed to gaze at FDA approved information. I do know physicians able to read X-rays, but the continuous glucose monitor are only allowed to be looked when the patient is on an rapid acting analog subq insulin, on office visits. Crazy world aye?
|
|
|
Post by joeypotsandpans on Jan 17, 2018 17:10:53 GMT -5
I don't think it's in the financial interest of shorts to post FUD, but many of them do think that -- especially those who post on StockTwits and Yahoo. In my opinion only, I believe there are "longs" on this board who are really short posting unrealistic expectations of the company to create long demand. I remember the days when people were saying that Sam Finta was fictitious and never was in the trials. Then he magically appeared before the ADCOMM panel and gave his very moving testimonial, and also had no conflict of interest (financial) other than his life and keeping this wonderful innovation alive....and they call me a conspiracy theorist regarding the actual conflict of interests inherent with a certain former FDA commissioner and columnists (rolls eyeballs) LOLOL!!
|
|
|
Post by hellodolly on Jan 18, 2018 6:40:24 GMT -5
In my opinion only, I believe there are "longs" on this board who are really short posting unrealistic expectations of the company to create long demand. I remember the days when people were saying that Sam Finta was fictitious and never was in the trials. Then he magically appeared before the ADCOMM panel and gave his very moving testimonial, and also had no conflict of interest (financial) other than his life and keeping this wonderful innovation alive....and they call me a conspiracy theorist regarding the actual conflict of interests inherent with a certain former FDA commissioner and columnists (rolls eyeballs) LOLOL!! And just last week we had the new FDA Commissioner, Scott Gottlieb, bantering on Twitter with Adam Fartstain. I wonder where those conflicts of interest might be?
|
|
|
Post by hellodolly on Jan 5, 2019 8:19:35 GMT -5
2015 - 19,604 (Sanofi Controlled) 2016 - 16,005 (Sanofi Partnership terminated Jan 2016) 2017 - 17,379 (MNKD controlled) 2018 - 27,624 (TV ads roll, STAT published) Who came the closest to predicting the correct number of scripts? Well, you did cretin11. Congrats on the guesswork. It was certainly refreshing to read so many messages from a year ago.
|
|
|
Post by mytakeonit on Jan 5, 2019 14:49:38 GMT -5
Didn't the rules stipulate ... the closest guess without going over Here go back to the end of page 6 and the beginning of page 7 and review ... "Nevermind"
|
|